June 21, 2007 -- China Biopharma (Bulletin Board: CBPC ) signed a deal with Soonfast Pharmaceutical Service & Technology Co., Ltd., giving China Biopharma the right to introduce an antiviral medicine for human papillomavirus (HPV) and herpes simplex virus (HSV) in the US and Europe. The medication is a natural, topical drug that has been shown in tests to inhibit the growth of HPV and HSV. In two to three days, it reduced the infection from the virus by 90%. China Biopharma and Soonfast will join in conducting tests in China and the US to obtain regulatory permission to market the herbal drug as an OTC medication. More details...
